177Lu-DOTATATE

Open Access
Bone Marrow Absorbed Doses and Correlations with Hematologic Response During ¹⁷⁷Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases
Linn Hagmarker, Johanna Svensson, Tobias Rydén, Martijn van Essen, Anna Sundlöv, Katarina Sjögreen Gleisner, Peter Gjertsson and Peter Bernhardt

Journal of Nuclear Medicine October 1, 2019, 60 (10) 1406-1413; DOI: https://doi.org/10.2967/jnumed.118.225235
You have access
Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Hendrik Bergsma, Kirsten van Lom, Marc H.G.P. Raaijmakers, M. Konijnenberg, B.L. Boen L.R. Kam, Jaap J.M. Teunissen, Wouter W. de Herder, Eric P. Krenning and Dik J. Kwekkeboom

Journal of Nuclear Medicine March 1, 2018, 59 (3) 452-458; DOI: https://doi.org/10.2967/jnumed.117.189712
You have access
NAMPT Inhibitor GMX1778 Enhances the Efficacy of ¹⁷⁷Lu-DOTATATE Treatment of Neuroendocrine Tumors
Anna-Karin Elf, Peter Bernhardt, Tobias Hofving, Yvonne Arvidsson, Eva Forssell-Aronsson, Bo Wängberg, Ola Nilsson and Viktor Johanson

Journal of Nuclear Medicine February 1, 2017, 58 (2) 288-292; DOI: https://doi.org/10.2967/jnumed.116.177584
You have access
Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using ¹⁷⁷Lu-DOTATATE
Ezgi Ilan, Mattias Sandström, Cecilia Wassberg, Anders Sundin, Ulrike Garske–Román, Barbro Eriksson, Dan Granberg and Mark Lubberink

Journal of Nuclear Medicine February 1, 2015, 56 (2) 177-182; DOI: https://doi.org/10.2967/jnumed.114.148437

Main menu

User menu

Search

177Lu-DOTATATE

Pages